Nick Hodge has a fascinating tickler about a stock valued at 31x less than the intrinsic worth of it’s graphite rights, so essential to the production of graphite. Any ideas?
Please note that this is your publicly visible biography - we recommend not including any personal information (phone, email, address, etc.) and ONLY linking to any other pages or profiles you're comfortable sharing with everyone.
Another confounding matter in the decision to buy XOMA is the ongoing trial by pharmaceutical giant Abbvie to evaluate their already approved blockbuster drug Humira (Adalibumab) for yet another indication: non-infectious posterior uveitis. Should this ND[...]